Completed PHASE3 INTERVENTIONAL 3-arm NCT00772603

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures (PROSPER1)

Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Sponsor: Parexel

Conditions Epilepsies, Partial

Interventions 1200mg SPN-804 2400mg SPN-804 Placebo

Updated 7 times since 2017 Last updated: Dec 23, 2013 Started: Nov 30, 2008 Primary completion: Apr 30, 2010 Completion: Nov 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Epilepsies, Partial, this trial is completed. The trial is conducted by Parexel and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Parexel
Supernus Pharmaceuticals, Inc.

Data source: Supernus Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Atlanta, United States , Aurora, United States , Baytown, United States , Bethesda, United States , Blagoevgrad, Bulgaria , Bucharest, Romania , Camden, United States , Campulung Muscel, Romania , Chihuahua City, Mexico and 60 more locations